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1014-62 Comparison of Novel Strategy Therapies for 
Obstructive Hypertrophic Cardiomyopathy: Relation of 
Relief of Left Ventricular Outflow Obstruction to 
Improved Symptoms and Health-Related Quality of Life 
Parameters 
Saidi Mohiddin. Gina Rowe, Londa Hathaway, Eric Leifer, Nancy Leidy, Susan Biddle, 
Sue Marden, Dorothy Tripodi, Lameh Fananapazir, National Institutes of Health, 
Bethesda, MD 
Background: Left ventricular (LV) outflow obstruction is present in about a third of 
patients with hypertrophic cardiomyopathy (HCM), and may cause disabling symptoms. 
Alcohol septal ablation (ASA) and dual chamber (DDD) pacing have been proposed as 
alternative therapies tc cardiac surgery for relief of LV outflow obstruction. Methods: We 
compared the impact of ASA and DDD on LV gradient, symptoms and health-related 
quality of life (HRQL) in a randomized propective study involving 70 patients with 
obstructive HCM and drug-refractory symptoms. The demographic and clinical character- 
istics of the 2 arms were similar. Patients completed the SF-36 Health Survey and a 
symptom measure at baseline (prior to randomization), 3 and 6 months. Results: Both 
procedures significantly reduced the LV ouHlow gradients determined at cardiac cathter- 
ization: ASA arm, the mean (SD)gradient reduced from 105 (32) mm Hg to 33 (32) mm 
Hg [a change of 72 (37) mm Hg, or 69%; and DDD arm, from 101 (36) mmHg to 49 (39) 
mm Hg (a change of 51 (32) mm Hg, or 50%]. ASA resulted in significantly (about 20 mm 
Hg) greater reduction in LV gradient, p=O.O17. Of the 70 patients randomized. 32 DDD 
and 29 ASA were available for HRQL analysis. Both therapies resulted in significant and 
equal improvement in all symptom and HRQL outcomes from baseline to 3 months, with 
no further change at 6.month follow-up. There was no significant correlation between 
changes in symptoms or HRQL and reductions in LV gradients, perhaps due to the 
dynamic nature of the LV outflow obstruction. Conclusions: (1) ASA and DDD are both 
effectwe in relieving LV obstruction in most patients; and 2) both DDD and ASA are asso- 
ciated with significant symptom and HRQL benefits at 3 months that persist to 6 months. 
As the symptomatic and HRQL benefits were equivalent, DDD pacing should perhaps be 
tried first. ASA may then be performed in patients with residual obstruction and symp- 
toms without ccncerns about Inducing heart block. 
1014-63 Septal Ablation for Symptomatic Hypertrophic 
Obstructive Cardiomyopathy: An Analysis of the 
Patients With Dissatisfactory Intervention Results 
Lothar Faber -I Dirk Welge, Peer Ziemssen. Hubert Seggewiss, Dieter Fassbender, Dieter 
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Background: In 90% of the patients (pts). with symptomatic hypertrophic obstructive 
cardiomyopathy (HOCM) the outilow gradient (LVOTG) can significantly be reduced or 
removed by septal ablation (PTSMA). Pts. with a dissatisfactory LVOTG response are 
not yet characterized sufficiently. 
Results: From 279 pts. reevaluated 3 months after PTSMA, 36 (13%) had PTSMA fail- 
ure (PF) defined as a less than 50% LVOTG reduction. On average, these pts. were 
younger (50*16 vs. 54*14 years; pcO.Ol), had a thicker septum (22+4 vs. 20&4 mm; 
pcO.O5), a higher baseline LVOTG (69*33 vs. 56233 mm Hg; p<O.Ol). and a lower CK 
release after PTSMA (477*228 vs. 556*272U/l; p<O.O5). 
The main cause for PF was an insufficient PTSMA lesion on PD-echo at follow-up (n=22; 
successful re-PTSMA in 6 pts.. surgery in 1 pt. and spontaneous LVOTG reduction in 6 
pts. within the following 12 months). Suboptimal scar localization, observed in 7 pts. 
treated before routine echocardiographic guidance (MCE) for PTSMA and requiring a re- 
PTSMA in 4 pts. and surgery in 2 pt., was not seen with MCE-guidance any more. 
Another group of pts. with PF showed persisting SAM and LVOTG despite a sufficient 
PTSMA scar due to excessive elongation of the mitral leaflets (n=5; spontaneous LVOTG 
elimination in one of them within 12 months). One pt. each had coexistent fibromuscular 
subaortic stenosis and severe midcavity obstruction which both did not respond tc 
PTSMA. 
Conclusions: Even with MCE guiding, younger pts. with a thicker septum, and those 
with markedly elongated mitral leaflets seem to be less suitable for PTSMA. Further- 
more. LVOTG elimination may need up to 1 year. Pre-interventional pt. selection, 
echocardiographic assessment, and pt. information should take these findings into con- 
sideration. 
1014-64 Prevalence and Spectrum of Thin Filament Mutations in 
Patients With Hypertrophic Cardiomyopathy: A 
Comprehensive Mutational Analysis of Troponin T, 
Troponin I, Alpha Tropomyosin, and Cardiac Actin 
Sara L. Van Driest, Erik G. Ellsworth, Melissa L. Will, Bernard J. Gersh, Steve R. 
Ommen, Michael J. Ackerman, Mayo Clinic, Rochester, MN 
Background: Thin filament mutations are reported tc cause -20% of Hypertrophic Car- 
diomyopathy (HCM) and display a dwerse phenotype. However, the frequency of these 
mutations and their associated phenotype in a single large cohort have not been 
reported. We determined the prevalence and spectrum of mutations in the genes encod- 
mg the thin filament proteins cardiac troponin T (TNNT2), cardiac troponin I (TNN13), 
alpha tropomyosin (TPMI), and cardiac actin (ACJC) in a large cohort of unrelated HCM 
patients, and searched for defining clinical characteristics for thin filament-HCM. 
Methods: DNA from 395 unrelated patients with HCM was obtained and analyzed. Muta- 
tional analysis of all protein coding excns of TNNTZ (15 exons), TNN13 (6). TPMi (9), 
and ACTC (6) was performed using polymerase chain reaction, denaturing high perfor- 
mance lkquid chromatography, and DNA sequencing. The clinical data ware maintained 
In a database independent of the patient genotype. 
Results: Overall, only 19 patients (4.6%) were identified having 12 distinct thin filament 
mutations: 9 with TNNT2 mutations, 6 with TNN13mutations, 3 with JPMl mutations, 
and 1 with an ACTC mutation. Of the 12 unique missense mutations identified, 6 (67%) 
were novel mutations. As a group. patients with thin filament mutations were not signifi- 
cantly different from the rest of the cohort in age at diagnosis, left ventricular wall thick- 
ness (LVWT), gradient, or family history of HCM or sudden death. However, when 
compared to patients with beta myosin heavy chain mutations (n=54), patients with thin 
filament mutations had less hypertrophy (LVWT = 19.6 f 6 mm versus 24.3 * 6 mm, p= 
0.04). 
Conclusions: This study represents a comprehensive evaluation for mutations in the 
genes encoding the thin filament of the cardiac sarccmere at a large, tertiary referral cen- 
ter for HCM. Here, thin filament mutations were identified in ~5% of the HCM cohort. 
Moreover, except for a lesser degree of hypertrophy when compared to patients with 
thick filament HCM on the basis of mutations in the beta myosin heavy chain, there were 
no cllnical features to distinguish this small subset of thin filament-HCM from HCM due to 
mutations in other genes. 
1014-65 Evidence That Left Ventricular Outflow Tract 
Obstruction Is a Predictor of Outcome in Patients With 
Hypertrophic Cardiomyopathy 
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Background. One of the most visible and quantifiable features of hypertrophic cardiomy- 
opathy (HCM) has been the left ventricular (LV) ouHlow tract gradient. Major therapeutic 
interventions (such as surgery, alcohol septal ablation and pacing) have been introduced 
to relieve subaortic obstruction and disabling symptoms. However, the significance of LV 
ouHlow obstruction with regard to clinical outcome in HCM has been the subject of con- 
troversey and remains incompletely unresolved. 
Methods. We assessed the impact of LV ouHlow gradient on mortality and morbidity I” a 
large HCM cohort prospectively followed ever 6.3k6.2 years. 
Results. Df 1101 consecutive patients, 127 (12%) died of HCM and 196 (18%) devel- 
oped severe progressive heart failure-related symptoms (NYHA functional classes III/IV): 
at initial evaluation, 273 study patients (25%) had LV outilow obstruction under basal 
conditions with continuous wave Doppler (gradient, =Omm Hg). Probability of HCM- 
related mortality and progression to severe disabling symptoms was significantly greater 
in patients with outilow obstruction than in those without (OR 2.0 and 4.4, respectively; 
pcO.0001 for both end-points), and was most substantial in obstructive patients 2 40 
years old (p<O.OOl). HCM mortality and morbidity due to obstruction did not increase with 
greater magnitude of gradient above the threshold of 30mm Hg. Multivariate analysis 
showed outflow obstruction to be a strong and independent predictor of HCM-mortality 
and severe symptoms (OR 1.6; p=O.O18) among several other disease variables. Likeli- 
hood of sudden death was also greater in patients wth obstruction (OR 1.9; p=O.O14), 
although the positive predictive value for obstruction was low (i.e., only 7%). 
Conclusions. Basal LV outflow obstruction (gradient, ?3Omm Hg) IS a strong and inde- 
pendent predictor of progression to severe symptoms and cardiovascular mortality in 
HCM. Therefore, treatment interventions that reduce outflow gradients can be expected 
to favorably influence quality of life and long-term prognosis in severely symptomatic 
patients with obstructive HCM, and could possibly be justified somewhat earlier at lesser 
gradients than is current practice. 
1014-66 Lefi Atrial Volumetric Remodeling Predicts Functional 
Capacity in Hypertrophic Cardiomyopathy 
Vandana Sachdey Charles W. Birdsall, Dorothy Tripodi, lnez Ernst, Lameh 
Fananapazir, Jonathan F. Plehn, National Heart, Lung and Blood Institute, Bethesda, MD 
Background: Left atrial volumetric remodeling (LAR) is a marker of hypertensive left ven- 
tricular (LV) hypertrophy and associated cardiovascular events and probably represents 
chronic hemodynamic overload. Its role as an indicator of disease severity in primary 
hypertrophic cardiomyopathy (HCM) has not been reported. We, therefore, compared 
the association of two-dimensional echocardiographically-determined LAR and other 
structural and hemodynamic parameters with objective measures of exercise functional 
capacity in 26 patients (14 males, 12 females, mean age=37 years) 
Methods: BSA-normalized left atrial volume by modified Simpson’s biplane method, M- 
mode (MM) and trans-mitral Doppler (E/A ratio) echocardiographic measures were 
obtained in patents undergoing cardiac catheterization within 24 hours of echocardio- 
graphic assessment and correlated with metabolic treadmill stress testing performed dur- 
ing the same admission. Magnetic rescnance imaging (MRI)-determined LV mass was 
also obtained in a subset of 13 subjects. 
Conclusions: Volumetric LAR in HCM patients correlated significantly and consistently 
with metabolic stress testing parameters. LAR predicted objective functional capacity at 
least as well as resting invaswe hemodynamic assessment and was superior to other 
forms of echocardiographic and MRI LV mass assessment 
